As a clinician and researcher, Dr. Kan Ding has a special interest in post-traumatic epilepsy and critical care EEG monitoring. Read More
Dr. Beh completed a multi-center fellowship in 2014 that included training at Johns Hopkins Medicine, New York University Medical Center and UT Southwestern in neuroimmunology, neuro- ophthalmology, and neuro- otology. Read More
Dr. Leston was most recently in private practice in St. Louis, MO, and also maintained a faculty appointment at Washington University. Read More
Drs. Roger Rosenberg and Juan Pascual are co-editors of the latest edition of Rosenberg's Molecular and Genetic Basis of Neurologic and Psychiatric Disease. The textbook provides a comprehensive introduction and reference to the foundations and key practical aspects relevant to the majority of neurologic and psychiatric disease. It will be released in November 2014.Added August 06, 2014 - Publications
DaiWai Olson, Ph.D., R.N., was chosen as a fellow of the Neurocritical Care Society. Dr. Olson is only the second nurse to receive this honor. The Neurocritical Care Society has a worldwide membership of healthcare professionals and is dedicated to improving outcomes for patients with life-threatening neurological illnesses.Added August 06, 2014 - Awards
Darin Okuda, M.D. and his colleagues conducting a multi-national study found that individuals with radiologically isolated syndrome (RIS) are at risk for a first clinical attack related to demyelination within the central nervous system; the risk appears to be predicated on age, sex, and the presence of cervical or thoracic spinal cord lesions.
Divyanshu Dubey, M.D., neurology resident, presented two papers at the 2014 International Stroke Conference. Dr. Dubey's work research focused on a combination therapy for ischemic stroke and smartphone applications for stroke.
Susan Iannaccone, M.D.'s, clinical trial of a drug for children with Spinal Muscular Atrophy (SMA) has had promising results. The drug manufacturer, ISIS Pharmaceuticals, reported the drug was well-tolerated at all dose levels and improved disease characteristics. Phase 3 trials are planned for later this year.